Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

Similar articles for PubMed (Select 23300757)

1.

Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.

Han Y, Huang H, Xiao Z, Zhang W, Cao Y, Qu L, Shou C.

PLoS One. 2012;7(12):e52745. doi: 10.1371/journal.pone.0052745. Epub 2012 Dec 27.

2.

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.

Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.

BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.

3.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

4.

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.

Clin Cancer Res. 2005 Mar 15;11(6):2149-55.

5.

Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.

Komatsu M, Hiyama K, Tanimoto K, Yunokawa M, Otani K, Ohtaki M, Hiyama E, Kigawa J, Ohwada M, Suzuki M, Nagai N, Kudo Y, Nishiyama M.

Mol Cancer Ther. 2006 Mar;5(3):767-75.

6.

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

7.

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.

J Clin Oncol. 2007 Feb 10;25(5):517-25. Retraction in: J Clin Oncol. 2012 Feb 20;30(6):678.

8.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2005 Nov 1;23(31):7911-8. Epub 2005 Oct 3.

9.

A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.

Kang J, D'Andrea AD, Kozono D.

J Natl Cancer Inst. 2012 May 2;104(9):670-81. doi: 10.1093/jnci/djs177. Epub 2012 Apr 13.

10.

Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy.

Bachvarov D, L'esperance S, Popa I, Bachvarova M, Plante M, Têtu B.

Int J Oncol. 2006 Oct;29(4):919-33.

PMID:
16964388
11.

Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.

Yoshikawa T, Takano M, Kita T, Kudoh K, Sasaki N, Kato M, Watanabe A, Miyamoto M, Goto T, Furuya K.

Eur J Gynaecol Oncol. 2012;33(3):269-73.

PMID:
22873097
12.

Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).

Gronlund B, Høgdall EV, Christensen IJ, Johansen JS, Nørgaard-Pedersen B, Engelholm SA, Høgdall C.

Int J Biol Markers. 2006 Jul-Sep;21(3):141-8.

PMID:
17013795
13.

Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.

Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-57-S15-61.

PMID:
9346224
14.

Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer.

Chaudhry P, Srinivasan R, Patel FD, Gopalan S, Majumdar S.

Int J Cancer. 2008 Apr 15;122(8):1716-21.

PMID:
18092329
15.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
16.

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.

17.

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.

Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J.

Clin Cancer Res. 2005 Sep 1;11(17):6300-10.

18.

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.

Clin Cancer Res. 2005 Aug 15;11(16):6030-9.

19.

ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.

Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.

J Clin Oncol. 2007 Nov 20;25(33):5172-9.

20.

Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.

Kong SY, Han MH, Yoo HJ, Hwang JH, Lim MC, Seo SS, Yoo CW, Kim JH, Park SY, Kang S.

Ann Surg Oncol. 2012 May;19(5):1707-12. doi: 10.1245/s10434-011-1943-5. Epub 2011 Jul 21.

PMID:
21833668
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk